BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Custirsen sodium: Phase III delayed

OncoGenex disclosed in its 2Q11 earnings that it will delay the start of a Phase III trial of OGX-011 in combination with first-line chemotherapy after partner Teva reported data from a drug-drug interaction study showing that OGX-011 may inhibit enzymes...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >